Company · CIK 0001880438
AN2 Therapeutics, Inc.
ANTXSearch this company’s filings
Search features10 guest searches · Free accounts get 10 a day · No credit card
Market data
Price
$4.53−$0.16 (−3.41%)
ANTX · Last trade
- Prev close
- $4.69
- Range (30d)
- $3.37 – $5.71
On the record
Recent filings
- 144ANTXAN2 Therapeutics, Inc.0001972481-26-000263 · 6.1 KBSEC(opens sec.gov)
- 10-QANTXQuarterly update0001193125-26-344569 · 9.3 MBSEC(opens sec.gov)
- 8-KANTXCurrent report0001193125-26-344549 · 364.6 KBSEC(opens sec.gov)
- 8-KANTXCurrent report0001193125-26-262264 · 164.2 KBSEC(opens sec.gov)
- 8-KANTXCurrent report0001193125-26-257430 · 191.6 KBSEC(opens sec.gov)
- 10-QANTXQuarterly update0001193125-26-216755 · 8.1 MBSEC(opens sec.gov)
- 8-KANTXCurrent report0001193125-26-216752 · 310.3 KBSEC(opens sec.gov)
- 8-KANTXCurrent report0001193125-26-149822 · 400.7 KBSEC(opens sec.gov)
- 8-KANTXCurrent report0001193125-26-117765 · 142.9 KBSEC(opens sec.gov)
- 10-KANTXAnnual report0001193125-26-110693 · 10.4 MBSEC(opens sec.gov)
Insiders
- Adjuvant Capital GP, L.P.10% Owner
- Adjuvant Global Health Technology Fund DE, L.P.10% Owner
- Adjuvant Global Health Technology Fund, L.P.10% Owner
- Aziz KabeerDirector
- Chanda SanjayChief Development Officer
- Day LucyChief Financial Officer
- Easom EricDirector, Chief Executive Officer
- Eckburg PaulChief Medical Officer
- Eizen Joshua MSee Remarks
- FitzPatrick Margaret MDirector
Tickers
Addresses
business
1300 EL CAMINO REAL, SUITE 100
MENLO PARK, CA, 94025
mailing
1300 EL CAMINO REAL, SUITE 100
MENLO PARK, CA, 94025
Same industry